Poly-gamma-DPGA Chelates Inhibit Anthrax Toxin Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anthrax countermeasures, including vaccines and therapies, have limitations such as side effects, high costs, and ineffectiveness against the inhalational form of the disease, highlighting a need for cheap and effective methods to inhibit anthrax toxin entry into cells.
Innovation Solution
Administering poly-γ-Glutamic acid-Fe(III) chelates to inhibit anthrax toxin and anthrax toxin protein entry into cells, utilizing their ability to form complexes with PA and prevent toxin-mediated cytotoxicity, thereby modulating anthrax toxin-mediated disease conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If poly-γ-DLPGA is used to inhibit anthrax toxin, then toxin entry into cells is reduced, but the presence of L-Glu isomers reduces binding affinity and effectiveness
Solution Approach 1:
The patent applies local quality by ensuring that only the D-Glu monomer units in the poly-γ-DPGA polymer chain contribute to toxin binding, while excluding L-Glu isomers. This creates a polymer with non-uniform chiral properties where each D-Glu unit serves the specific function of high-affinity toxin binding, resolving the contradiction by achieving pure D-Glu composition through controlled fermentation conditions.
Solution Approach 2:
The patent changes the chiral parameter of the glutamic acid monomers from a racemic mixture (containing both D and L isomers) to exclusively D-Glu isomers. This parameter change in monomer composition directly improves toxin binding affinity and inhibition effectiveness, while the controlled biological synthesis method maintains ease of manufacture.
2Ease of manufacture
If poly-γ-DPGA is produced through biological synthesis, then production cost is reduced, but purification and stereochemical control become more difficult
Solution Approach 1:
The patent employs self-service by utilizing the inherent stereochemical specificity of D-Glu-producing bacteria (such as Bacillus licheniformis) to naturally synthesize only D-Glu monomers during fermentation. The biological system itself ensures stereochemical purity without requiring external intervention for separation or purification, thus maintaining both low production cost and high manufacturing precision.
Solution Approach 2:
The patent changes the synthesis method from chemical polymerization to biological fermentation, which inherently produces D-Glu isomers with high stereochemical purity. This parameter change in the synthesis approach simultaneously achieves cost reduction through biological production and maintains precision through the enzyme-specificity of the fermentation process.
3Reliability
If complex anthrax vaccines and therapies are used, then protection against anthrax is achieved, but side effects and costs increase
Solution Approach 1:
The patent extracts only the essential protective component (poly-γ-DPGA) from the complex anthrax vaccine system, eliminating unnecessary adjuvants and other vaccine components that cause side effects. This extracted polymer specifically targets toxin binding without triggering the adverse immune responses associated with traditional vaccines, thus maintaining protection while reducing harmful effects.
Solution Approach 2:
The patent uses poly-γ-DPGA, a natural capsule component of B. anthracis, as a decoy that copies the structure of the bacterial capsule without containing the toxic elements. This structural copy binds to the toxin and neutralizes it, providing protection similar to vaccines but without the side effects of immunization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The poly-γ-Glutamic acid-Fe(III) chelates significantly reduce anthrax toxin entry into cells, offering a prophylactic and therapeutic solution by inhibiting toxin-mediated cytotoxicity and providing protection against lethal toxin challenges in animal models.
Implementation Method 1
poly-γ-Glutamic acid-Fe(III) chelates
Implementation Method 2
form complexes with PA
Data Source
AI summary
Methods and compositions for inhibiting entry of an anthrax toxin and/or an anthrax toxin protein into a cell are provided. Aspects of the subject methods include administering to a host an effective amount of poly-γ-Glutamic acid-Fe(III) chelate. Also provided are compositions suitable for use in the subject methods, as well as pharmaceutical preparations thereof.